Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (December 2020)
22 slides from Noxopharm's investor presentation, Dec 8, 2020
Slide 1: ASX Announcement: Corporate Presentation for December Investor Webinar
For personal use only ASX Announcement | 8 December 2020 Noxopharm Limited (ASX:NOX) Noxopharm Corporate Presentation for December Investor Webinar Sydney 8 December 2020: Australian clinical‐stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide the following corporate pre
Slide 2: Forward Looking Statements
For personal use only Media Enquiries Julia Maguire The Capital Network E: julia@thecapitalnetwork.com.au T: + 61 2 8999 3699 Forward Looking Statements This announcement may contain forward‐looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”,
Slide 3: Webinar Presentation December 2020
For personal use only Noxopharm Limited (ASX:NOX) WEBINAR PRESENTATION DECEMBER 2020 Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 1
Slide 4: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not Although the Company believes that the expectations reflected in the forward looking statements be considered as an offer or invitation to subscribe for, or purchase any shar
Slide 5: Our single-minded objective
Our single-minded objective ……. For personal use only ☛ is to prove that Veyonda® ☛ is the answer to unlocking the power of the immune system to fight cancer ☛ allowing the 3 main forms of cancer therapy - immuno-oncology, radiotherapy, chemotherapy - to reach their full potential ☛ identifying Noxo
Slide 6: Key R&D achievements in 2020
Key R&D achievements in 2020 ……. For personal use only DARRT-1 Phase 1b Exciting early study provides median overall 2 Independent evidence of proof- survival data studies confirming of-concept of emerging from that Veyonda works abscopal responses LuPIN study by converVng Bristol-Myers tumours from
Slide 7: We go into 2021
We go into 2021 ……. For personal use only ☛ with a strong cash posiVon (based on $23M CR and an;cipated R&D Rebate) ☛ providing a full 12-month runway ☛ to meet aim of a[aining proof-of-concept of Veyonda as a major new drug prospect 2020 Noxopharm. All rights reserved.
Slide 8: Veyonda joins the new wave of cancer immuno-oncology therapies
Veyonda joins the new wave of cancer For personal use only immuno-oncology (I-O) therapies ……. ☛ that aim to restore the body’s immune system to fight cancer ☛ are the acknowledged future of cancer therapy ☛ re-acVvaVng the immune system is readily achieved ☛ the problem is getting the reactivated im
Slide 9: Restoring immune function to tumours
Restoring immune funcVon to tumours For personal use only T T T T T T T T Veyonda® T T COLD T T T HOT T T T T All healthy tissues Emerging cancer cells With tumour now fully Veyonda block S1P production by cancer cells contain immune cells established, ongoing high (T cells) T S1P levels keep immune
Slide 10: Employing the unique 'COLD to HOT' Veyonda function
Employing the unique ‘COLD to HOT’ Veyonda funcVon For personal use only PD-1 IONIC Program therapy Veyonda + checkpoint (PD-1) inhibitors Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy LuPIN Program Radio- Veyonda + (intravenous) radiotherapy therapy Source: Enhancing Immunothe
Slide 11: Employing the unique 'COLD to HOT' Veyonda function
Employing the unique ‘COLD to HOT’ Veyonda funcVon For personal use only PD-1 IONIC Program therapy Veyonda + checkpoint (PD-1)inhibitors Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy LuPIN Program Radio- Veyonda + (intravenous) radiotherapy therapy Source: Enhancing Immunother
Slide 12: PD-1 IONIC Program: checkpoint inhibitors
PD-1 IONIC Program For personal use only therapy Veyonda + checkpoint inhibitors 2019 sales of checkpoint inhibitors US$22 billion Search for Checkpoint Inhibitor partners • Keytruda® Merck • Opdivo ® Bristol-Myers Squibb • Yervoy ® Bristol-Myers Squibb 10-30% response rates in 7 cancers (eg. lung,
Slide 13: IONIC-1: Veyonda + checkpoint inhibitor
PD-1 IONIC Program For personal use only therapy Veyonda + checkpoint inhibitors IONIC-1 Veyonda® + checkpoint Immuno-Oncology With inhibitor NOX66 In Combination Veyonda® + nivolumab (Opdivo®) (Bristol Myers Squibb) Bristol-Myers Squibb (NYSE:BMY) Market cap US$145 billion Pharma ranking 11th 2019
Slide 14: IONIC-1 clinical objectives
PD-1 IONIC Program For personal use only therapy Veyonda + checkpoint inhibitors IONIC-1 Clinical objecVve #1 Improve low (10-30%) response rates to Opdivo in responsive cancers (eg. lung, melanoma, bladder, kidney) Cohort 1. PaVents recently treated with Opdivo® with mild disease progression Phase
Slide 15: DARRT Program
Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy For personal use only Direct and Abscopal Response Transforming a local anti-cancer effect of radiation into a whole-of-body anti-cancer to Radiotherapy effect (abscopal response) Objectives: 1. To convert the abscopal response from
Slide 16: 4-step DARRT process
Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy For personal use only DARRT Program Radiotherapy 4-step DARRT process: Step 1. RadiaVon applied to single tumour Step 2. RadiaVon acVvates immune cells ResoluVon Partial abscopal Complete Step 3. Veyonda augments that local immune o
Slide 17: DARRT-1 completed study
Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy For personal use only DARRT-1 Completed 25 men late-stage progressive prostate cancer MetastaVc castraVon-resistant prostate cancer (mCRPC) No remaining standard treatment options Low-dose (palliaVve) radiotherapy (RT) to single sod
Slide 18: DARRT-1 results after 6 months
Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy For personal use only In paVents evaluable ader 6 months* ….. Over 50% Over 30% No drop in Abscopal drop in tumour PSA in pain response levels in growth 5/16 in 10/15 in 4/15 10/16 patients paVents paVents patients * 15 paVents elig
Slide 19: DARRT-2 Phase 2 study
Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy For personal use only DARRT-2 Phase 2 study 150 - 200 patients multi-national Parexel CRO Late-stage cancer. No remaining standard treatment opVons Final planning current. Enrolment to start H1 2021 Prostate cancer, breast cancer, l
Slide 20: LuPIN Program
LuPIN Program Radio- Veyonda + (intravenous) radiotherapy For personal use only therapy LuPIN program = Veyonda + 177lutetium-PSMA-617 for late-stage prostate cancer 177luteVum-PSMA-617 acquired by NovarVs in 2018 in US$6 billion transacVon St Vincent’s Hospital Sydney tesVng ability of LuPIN therap
Slide 21: Objectives
Objectives For personal use only Over the next 2.5 years, with a modest investment of shareholder funds, to show that …. IONIC Veyonda increases the response rate to nivolumab (Opdivo) (BMS), establishing its potential to boost checkpoint inhibitor drug sales well above current US$22 billion p.a. DA
Slide 22: An I-O therapy to transform the management of cancer
For personal use only Discover Develop Deliver An I-O therapy to transform the management of cancer www.noxopharm.com Media Enquiries Email: info@noxopharm.com The Capital Network Phone: (+61) 2 9144 2223 Julia Maguire +61 2 8999 3699 h[ps://www.linkedin.com/company/noxopharm-limited julia@thecapita